Vanguard Group’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Vanguard Group’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,500,305	Closed	-$7.37M	–	4460
2024 Q1	$7.37M	Buy	1,500,305 +19,986	+1%	+$94.9K	﹤0.01%	3129
2023 Q4	$5.4M	Buy	1,480,319 +15,477	+1%	+$42.4K	﹤0.01%	3259
2023 Q3	$3.25M	Buy	1,464,842 +94,054	+7%	+$263K	﹤0.01%	3426
2023 Q2	$4.66M	Buy	1,370,788 +33,429	+2%	+$121K	﹤0.01%	3340
2023 Q1	$5.34M	Buy	1,337,359 +16,498	+1%	+$72.6K	﹤0.01%	3278
2022 Q4	$7.19M	Sell	1,320,861 -14,154	-1%	-$83.3K	﹤0.01%	3118
2022 Q3	$6.71M	Sell	1,335,015 -62,504	-4%	-$308K	﹤0.01%	3157
2022 Q2	$5.33M	Buy	+1,397,519	New	+$8.92M	﹤0.01%	3350

Vanguard Group's TGAN Position: Q2 2024 in Review

Vanguard Group sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 1,500,305 shares — an estimated $7.37M sold.

Vanguard Group first reported a position in TGAN in Q2 2022 and held it in 8 quarters. The position peaked at $7.37M in Q1 2024. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Vanguard Group reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Vanguard Group sold 1,500,305 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $7.37M.
Vanguard Group first reported a position in Transphorm, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Vanguard Group's Transphorm, Inc. Common Stock position peaked at $7.37M in Q1 2024.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.